MDRNA Sells Manufacturing Business to Par Pharmaceuticals to Hone RNAi Focus | GenomeWeb

MDRNA this week said that Par Pharmaceuticals has agreed to purchase its manufacturing facilities in Hauppauge, NY, as well as its abbreviated new drug application for generic calcitonin-salmon nasal spray, for an undisclosed amount.

The agreement, which eliminates all of MDRNA's non-RNAi expenses, "represents the final step in our plan to create a company solely focused in the research and development of RNAi-based therapeutics," Michael French, president and CEO of MDRNA, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.